Cargando…

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency. For 2 patients, QT-interval prolongation but no arrhythmias occurred. Use of this t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maryandyshev, Andrey, Pontali, Emanuele, Tiberi, Simon, Akkerman, Onno, Ganatra, Shashank, Sadutshang, Tsetan Dorji, Alffenaar, Jan-Willem, Amale, Rohit, Mullerpattan, Jai, Topgyal, Sonam, Udwadia, Zarir Farokh, Centis, Rosella, D’Ambrosio, Lia, Sotgiu, Giovanni, Migliori, Giovanni Battista
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2017
Materias:	Dispatch
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621558/ https://www.ncbi.nlm.nih.gov/pubmed/28758888 http://dx.doi.org/10.3201/eid2310.170834

Ejemplares similares

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
por: Nasiri, Mohammad Javad, et al.
Publicado: (2022)

Tropical pulmonary eosinophilia - A review
por: Mullerpattan, Jai B., et al.
Publicado: (2013)

Effective use of telemedicine in Mumbai with a cohort of extensively drug-resistant “XDR” tuberculosis patients on bedaquiline during COVID-19 pandemic
por: Udwadia, Zarir F., et al.
Publicado: (2021)

775. An Epidemiological Analysis of Patients With Multidrug-Resistant Tuberculosis Among Tibetan Refugees in India
por: Desel, Tenzin, et al.
Publicado: (2018)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Who will teach the teachers: An analysis of the inhaler technique of Indian patients and health care providers in a tertiary health care centre
por: Mullerpattan, Jai Bharat, et al.
Publicado: (2016)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!
por: Tiberi, Simon, et al.
Publicado: (2018)

India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further
por: Udwadia, Zarir F, et al.
Publicado: (2021)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
por: Franke, Molly F., et al.
Publicado: (2021)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Erratum: Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid: A Prospective Multicountry Study
Publicado: (2021)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
por: Zhu, Hanzhao, et al.
Publicado: (2023)

New anti-tuberculosis drugs and regimens: 2015 update
por: D'Ambrosio, Lia, et al.
Publicado: (2015)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

1884. Clinical Outcomes Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline or Delamanid Containing Regimens
por: Kempker, Russell R, et al.
Publicado: (2019)

Adverse Drug Reaction Monitoring in Multidrug-Resistant Tuberculosis Patients Receiving Bedaquiline and Delamanid-Based Regimen
por: Paikray, Elisha, et al.
Publicado: (2022)

First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India
por: Tsundue, Tenzin, et al.
Publicado: (2022)

Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
por: Udwadia, Zarir F., et al.
Publicado: (2015)

Why “covering all” in the DOTS program is not necessarily “all being covered” by the DOTS program
por: Pinto, Lancelot Mark, et al.
Publicado: (2010)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid
por: Nieto Ramirez, Luisa Maria, et al.
Publicado: (2020)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai
por: Udwadia, Zarir F, et al.
Publicado: (2016)

Tuberculosis in the time of COVID-19: quality of life and digital innovation
por: Visca, Dina, et al.
Publicado: (2020)

Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating
por: Sotgiu, Giovanni, et al.
Publicado: (2021)

Recent developments in the diagnosis and management of tuberculosis
por: Sulis, Giorgia, et al.
Publicado: (2016)

Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)

Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Sotgiu, Giovanni, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0p934jnuloupds9hs1274lo106